OBJECTIVE:To observe therapeutic efficacy of Mecobalamin combined with domperidone in the treatment of diabetic gastroparesis (DG).METHODS:144 DG patients as subject were randomly divided into trial group and control group.Trial group received Mecobalamin injection combined with domperidone,and control group received domperidone only.The clinical efficacy,symptom scores and the rate of gastric emptying were compared between 2 groups.RESULTS:The total effective rate of trial group (93.06％) was better than that of control group (81.94％),there was statistical significance (P＜0.05).After treatment,the symptom scores of trial group were significantly lower than that of control group,and the rate of gastric emptying were significantly higher than in control group,the symptom scores of upper abdominal pain,epigastric discomfort,belching and decreased appetite in trial group were significantly lower than in control group after treatment,there was statistical significance (P＜0.05 or P＜0.01).There was no ADR in the treatment in both groups.CONCLUSIONS:Mecobalamin injection combined with domperidone can improve DG effectively.%目的:观察甲钴胺联合多潘立酮治疗糖尿病性胃轻瘫的临床疗效和安全性.方法:将144例糖尿病性胃轻瘫患者采用随机数字表法均分为试验组和对照组.在降糖治疗的同时,试验组患者给予甲钴胺注射液联合多潘立酮治疗,对照组患者仅给予多潘立酮治疗,治疗4周后比较两组患者的临床疗效、症状积分、胃排空率.结果:试验组总有效率(93.06％)显著高于对照组(81.94％),两组比较差异有统计学意义(P＜0.05)；治疗后试验组患者的症状积分显著低于对照组,胃排空率显著高于对照组,试验组患者上腹痛、上腹不适、嗳气及食欲下降等症状评分显著低于对照组,两组比较差异均有统计学意义(P＜0.05或P＜0.01).试验中两组患者均未见不良反应发生.结论:甲钴胺联合多潘立酮可有效改善糖尿病性胃轻瘫.
展开▼
